<DOC>
	<DOCNO>NCT00403754</DOCNO>
	<brief_summary>This study design provide data safety efficacy 3 dos indacaterol ( 150 , 300 , 600 µg ) Japanese asthma patient optimal dose , dos , could choose test late study .</brief_summary>
	<brief_title>Dose Ranging Study Indacaterol Japanese Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Male female Japanese asthmatic patient age 18 75 year old . Patients hospitalized emergency room treatment acute asthma attack 6 month prior first day screen screening period . Patients use tobacco product within 6 month prior first day screen smoke history great 10 pack year . Patients history malignancy exception localize basal cell carcinoma skin . Pregnant nursing ( lactate ) woman . Patients treatment disallow medication include investigational drug . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>asthma</keyword>
	<keyword>QAB149</keyword>
	<keyword>indacaterol</keyword>
	<keyword>long act β2-agonist</keyword>
	<keyword>bronchodilator</keyword>
</DOC>